Humacyte Inc HUMA
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if HUMA is a good fit for your portfolio.
News
-
Humacyte Board of Directors Strengthened with Addition of John P. Bamforth and Keith Anthony Jones
-
Pluristyx Announces License Agreement with Humacyte to Develop BioVascular Pancreas using iPSCs
-
Humacyte Shares Jump on FDA's Special Status Award
-
Humacyte Acellular Tissue Engineered Vessel (ATEV™) Receives FDA’s Regenerative Medicine Advanced Therapy (RMAT) Designation for Patients with Advanced Peripheral Artery Disease (PAD)
-
Humacyte Presents Positive Preclinical Data For Its BioVascular Pancreas (BVP™) Program
-
Centers for Medicare & Medicaid Services (CMS) Issues ICD-10-PCS Codes for Humacyte’s Human Acellular Vessel™ (HAV™)
-
Humacyte to Present at the Jefferies Global Healthcare Conference
-
Humacyte to Participate at Upcoming Investor Conferences in May
Trading Information
- Previous Close Price
- $8.15
- Day Range
- $7.86–9.00
- 52-Week Range
- $1.96–9.97
- Bid/Ask
- $7.91 / $7.98
- Market Cap
- $945.53 Mil
- Volume/Avg
- 3.9 Mil / 3.1 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Humacyte Inc is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 185
- Website
- https://www.humacyte.com
Comparables
Valuation
Metric
|
HUMA
|
IMVT
|
PTGX
|
---|---|---|---|
Price/Earnings (Normalized) | — | — | 16.51 |
Price/Book Value | 36.13 | 6.55 | 4.21 |
Price/Sales | — | — | 7.68 |
Price/Cash Flow | — | — | 12.62 |
Price/Earnings
HUMA
IMVT
PTGX
Financial Strength
Metric
|
HUMA
|
IMVT
|
PTGX
|
---|---|---|---|
Quick Ratio | 8.20 | 13.18 | 15.61 |
Current Ratio | 8.37 | 13.70 | 15.72 |
Interest Coverage | −15.49 | — | — |
Quick Ratio
HUMA
IMVT
PTGX
Profitability
Metric
|
HUMA
|
IMVT
|
PTGX
|
---|---|---|---|
Return on Assets (Normalized) | −60.89% | −44.70% | 51.28% |
Return on Equity (Normalized) | −219.00% | −49.06% | 56.32% |
Return on Invested Capital (Normalized) | −136.12% | −53.44% | 51.24% |
Return on Assets
HUMA
IMVT
PTGX
Biotechnology Industry Comparables
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
---|---|---|---|---|---|---|
Novo Nordisk A/S ADR
NVO
| Nkqjrdkd | Lcstk | $565.6 Bil | |||
Vertex Pharmaceuticals Inc
VRTX
| Flzmlhyk | Yhzbypm | $127.8 Bil | |||
Regeneron Pharmaceuticals Inc
REGN
| Vlrwhmrx | Vkcxnj | $117.3 Bil | |||
Moderna Inc
MRNA
| Hhckvjl | Fjn | $46.1 Bil | |||
Alnylam Pharmaceuticals Inc
ALNY
| Rybbffp | Brbrlx | $29.7 Bil | |||
argenx SE ADR
ARGX
| Wzlfzxqsz | Xtd | $28.8 Bil | |||
BioNTech SE ADR
BNTX
| Frddntywf | Dvxrc | $20.7 Bil | |||
Biomarin Pharmaceutical Inc
BMRN
| Cxfrdkbt | Vfrztk | $16.1 Bil | |||
United Therapeutics Corp
UTHR
| Zpxyblrb | Bzc | $14.9 Bil | |||
Incyte Corp
INCY
| Rrqdsthn | Szgyjj | $13.5 Bil |